Biogen surges 40 after stunning reversal sees it revive plans for Alzheimer s treatment BIIB
Get the Full StoryGlassdoor BiogenShares of Biogen surged more than 40 on Tuesday morning after the company announced plans to seek approval for an experimental Alzheimer's treatment called aducanumab.
Investors welcomed the news after the company's shares plummeted 29 in March when Biogen said it would abandon the therapy following two failed clinical trials.
The company said it decided to revisit submitting the therapy for approval following a new analysis of the data from the failed trials and a series of discussions with the Food and Drug Administration.
Watch Biogen trade live on Markets Insider.
Biogen's stock price charged more than 40 higher on Tuesday morning after the company said it would submit an Alzheimer's treatment for regulatory approval.
The biotechnology company made the decision to revive the experimental therapy called aducanumab following a new analysis of data from failed clinical trials and a series of discussions with the Food and Drug Administration. See the rest of the story at Business InsiderNOW WATCH: Most maps of Louisiana aren't entirely right. Here's what the state really looks like.See Also:The best smartwatches you can buyThe 10 richest royal families in Europe, rankedHealthcare stocks are badly lagging the market this year. Here's why a top strategist at 2.9 trillion State Street says they're set to rally.
Share: